Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylphenidate
Drug ID BADD_D01431
Description Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally inappropriate symptoms associated with ADHD: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Long-acting formulations of psychostimulants such as methylphenidate, [DB01576], and [DB01255] are considered the most effective and widely used treatment for ADHD, and are considered first-line options for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.
Indications and Usage For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
Marketing Status Prescription; Discontinued
ATC Code N06BA04
DrugBank ID DB00422
KEGG ID D04999
MeSH ID D008774
PubChem ID 4158
TTD Drug ID D02PPN
NDC Product Code 70165-200; 68968-5554; 0406-7654; 0781-2361; 0781-2364; 68968-5553; 68968-5555; 70165-100; 70165-300; 68968-5552; 0781-2363; 0781-2362
Synonyms Methylphenidate | Metadate | Equasym | Methylin | Concerta | Phenidylate | Ritalin | Ritaline | Ritalin-SR | Ritalin SR | Tsentedrin | Centedrin | Daytrana | Methylphenidate Hydrochloride | Hydrochloride, Methylphenidate
Chemical Information
Molecular Formula C14H19NO2
CAS Registry Number 113-45-1
SMILES COC(=O)C(C1CCCCN1)C2=CC=CC=C2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityBeta-2 adrenergic receptorP07550T525229187524; 7913199; 8382844; 6147001; 1957308; 7716792; 12616289
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Antisocial behaviour19.05.01.0100.000184%Not Available
Anxiety19.06.02.0020.011752%
Apathy19.04.04.0020.001836%Not Available
Aphasia19.21.01.001; 17.02.03.001--
Aplastic anaemia01.03.03.0020.000048%Not Available
Apnoea22.02.01.0010.000184%
Appendicitis11.01.07.001; 07.19.01.0010.000551%
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Arrhythmia02.03.02.0010.002663%Not Available
Arteriospasm coronary24.04.04.005; 02.02.02.0050.000551%Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.0100.001194%Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.002--
Atrioventricular block first degree02.03.01.0040.000275%
Atrioventricular block second degree02.03.01.0050.000459%
Attention deficit/hyperactivity disorder19.21.04.0010.002112%Not Available
Auricular swelling04.01.01.002--Not Available
Autism19.22.02.001; 17.03.05.0010.000275%Not Available
Autoimmune hepatitis10.04.09.001; 09.01.07.0190.000184%Not Available
Back pain15.03.04.005--
Benign hepatic neoplasm16.06.01.001; 09.04.01.0010.000184%Not Available
Benign intracranial hypertension17.07.02.0010.000367%Not Available
Binge eating19.09.01.0010.000184%Not Available
Bipolar I disorder19.16.01.0020.000184%Not Available
Blindness17.17.01.003; 06.02.02.0010.000643%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood bilirubin increased13.03.01.008--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 27 Pages